Invesco Ltd. Sellas Life Sciences Group, Inc. Transaction History
Invesco Ltd.
- $600 Billion
- Q3 2025
A detailed history of Invesco Ltd. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 50,179 shares of SLS stock, worth $71,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,179
Previous 50,166
0.03%
Holding current value
$71,755
Previous $109,000
26.61%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SLS
# of Institutions
100Shares Held
27.8MCall Options Held
3.85MPut Options Held
126K-
Vanguard Group Inc Valley Forge, PA6.84MShares$9.78 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX6.03MShares$8.63 Million1.59% of portfolio
-
Marshall Wace, LLP London, X02.36MShares$3.37 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.26MShares$3.24 Million0.0% of portfolio
-
State Street Corp Boston, MA1.36MShares$1.95 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $29.4M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...